top of page

Browse by category

Search

REDEFINE 2: CagriSema demonstrates superior weight loss

REDEFINE 2: CagriSema demonstrates superior weight loss

Outcomes from the from REDEFINE 2, a phase 3 trial in the global REDEFINE programme, have revealed the trial achieved its primary...

REDEFINE 1 trial: CagriSema demonstrates superior weight loss in adults with obesity or overweight

REDEFINE 1 trial: CagriSema demonstrates superior weight loss in adults with obesity or overweight

Headline results from Novo Nordisk’s REDEFINE 1 has shown that the trial achieved its primary endpoint by demonstrating a statistically...

Novo Nordisk to initiate study assessing CagriSema vs Tirzepatide

Novo Nordisk to initiate study assessing CagriSema vs Tirzepatide

Novo Nordisk is planning a study that will see CagriSema, a new investigational medicine developed by Novo that combines Cagrilintide and...

BMS demonstrates superior efficacy over non-surgical treatments in managing obesity and associated metabolic disorders

2 days ago

Sucralose alters brain activity related to hunger and increases appetite, especially in people with obesity

2 days ago

FDA approves Soleno’s VYKAT XR to treat hyperphagia in Prader-Willi Syndrome

2 days ago

Back to Top

bottom of page